Healthcare Industry News: total hip replacement
News Release - March 6, 2008
Smith & Nephew Launches R3(TM) Acetabular System a Revolution in Hip MotionMEMPHIS, Tenn. and SAN FRANCISCO, March 6 (HSMN NewsFeed) -- Smith & Nephew, Inc. (NYSE: SNN ; LSE: SN ) Orthopaedic Reconstruction business today announced the global launch of the R3(TM) Acetabular System, an advanced multi-bearing acetabular cup system used in total hip replacement procedures. The announcement was made during the 75th annual American Academy of Orthopaedic Surgeons (AAOS), the largest orthopaedic congress in the world, in San Francisco.
The R3 Acetabular Cup is engineered for multiple bearing options and features STIKTITE(TM) porous coating that is designed to enhance fixation and bony in-growth. The multi-bearing cup, in addition to providing flexibility for surgeons, provides a foundation designed to reduce wear and the subsequent need for revision surgery. Optimized inserts accommodate larger head sizes and help the R3 system achieve a greater range of motion. By utilizing a single set of instruments for all bearings and as the first system for Smith & Nephew to offer disposable trial liners, the R3 Acetabular system gives surgeons one way to think differently.
"The R3 System is another example of our continuum of care in action. A surgeon now has more options to treat the patient and when combined with our excellent hip stems, the R3 system presents a high performance option that fits nicely into our growing portfolio of products for active patients," said Joseph DeVivo, president of Smith & Nephew Orthopaedic Reconstruction. "The R3 system represents how we listen to our customers and provide them with high tech answers to help their patients regain their lives."
"The R3 Acetabular system will now give me the flexibility to tailor the implant to each of my patients," said designer surgeon, Stephen McMahon, of the Malabar Orthopaedic Clinic in Windsor, Australia. "This range of options allows me to provide the most suitable surgical solution for each individual, enabling patients to realize their best possible outcome."
R3 modular resurfacing system and ceramic-on-ceramic system are currently awaiting FDA approval in the US.
(TM) Trademark of Smith & Nephew. Reg. U.S. Pat. & Tm. Off.
Smith & Nephew is a global medical technology business, specializing in Orthopaedic Reconstruction, Orthopaedic Trauma & Clinical Therapies, Endoscopy and Advanced Wound Management products. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.
Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The company has 8,800 employees and operates in 32 countries around the world. Annual Sales in 2007 were nearly $3.4 billion.
This press release contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. In particular, statements regarding planned growth in our business and in our trading margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim," "plan," "intend," "anticipate," "well-placed," "believe," "estimate," "expect," "target," "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward- looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.
All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
Source: Smith & Nephew
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsSmith & Nephew expands next-generation handheld robotic-assisted CORI(TM) Surgical System into total hip arthroplasty with RI.HIP NAVIGATION
Smith & Nephew's PICO(TM) 7 and PICO 14 Negative Pressure Wound Therapy Systems are the first systems indicated to aid in reducing the incidence of both deep and superficial incisional surgical site infections and dehiscence
Smith & Nephew acquires novel cementless partial knee system